Halozyme Therapeutics, Inc. (HALO) Posts Surprise Q2 Profit
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
EPS Growth %: +17.5%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- La-Z-Boy (LZB) Tops Q4 EPS by 44c, Beats on Revenue
- CarMax (KMX) Tops Q1 EPS by 35c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
